THU0256

RISK OF LONG-TERM INCIDENT CARDIOVASCULAR EVENT AND MORTALITY IN PATIENTS WITH SLE AND POPULATION CONTROLS IS ASSOCIATED WITH A HIGHER CAROTID INTIMA-MEDIA THICKNESS

Sofia Ajejanova^{1,2}, Ingiläid Hafström¹, Johan Frostegård¹. ¹Karolinska Institutet, Stockholm, Sweden; ²Vrije Universiteit Brussel, Brussels, Belgium

Background: Measurement of carotid intima-media thickness (cIMT) is promoted as one of the tools for cardiovascular (CV) risk assessment in primary prevention in general population. The diagnosis of systemic lupus erythematosus (SLE) is a strong risk factor for premature CV events and mortality. Whether assessment of cIMT has a value for prediction of CV morbidity and mortality in patients with SLE compared with population controls of similar age and sex is not established.

Objectives: To examine association of cIMT with risk of incident CV events and mortality in SLE and controls.

Methods: We used the cross-sectional SLEVIC (SLE vascular impact cohort study) cohort of consecutive patients with SLE aged <70 years who were regularly treated in a tertiary referral rheumatology center. Carotid ultrasound was performed at inclusion to the cohort (from September 2006 to January 2008) in 118 patients and in 122 population controls matched by age and sex. Incident CV events were defined as hospitalization for angina pectoris, myocardial infarction, bypass grafting, percutaneous coronary or peripheral artery intervention, ischemic stroke and TIA. Combined outcome of incident CV event and all-cause mortality was evaluated for a mean (SD) follow-up of 9.6 (1.5) years. Participants with prevalent CV before inclusion, n=18, and those who were lost to follow-up, n=14, were excluded from this analysis.

Event-free survival rates in patients and controls were compared using Kaplan-Meier curves. Relative hazard ratios from Cox proportional-hazards regression models were used to estimate the effect of cIMT measurement on the outcome.

Results: At inclusion, mean age (SD) of the included 99 patients was 47 (13) years, 87% females, mean disease duration 12 (9) years, SLEDAI 4.0, and SLICC/ACR 1.0. Mean age of included 109 controls was 49 (12) years, 91% females.

Baseline mean (SD) cIMT did not differ between the groups (p=0.345) and was 607 (127) μ m in patients and 623 (118) μ m in controls.

During follow-up, 12 patients and 4 controls were defined with the outcome. The outcome was reached more often in patients than in controls, p=0.022. The mean time to outcome (SD) was 9.9 (0.2) years for patients and 10.3 (0.1) years for controls.

The hazard rate (HR) for the combined outcome of CV event and mortality was 3.7-fold (95% CI, 1.2–11.5) higher in patients than in controls, adjusted for age, sex and smoking history, p=0.025. A higher baseline mean cIMT was significantly associated with the outcome, HR 1.0 (95% CI, 1.0-1.01) per 1.0 μ m increase in cIMT, p=0.040, irrespective of the group. Additional adjustment for traditional risk factors, disease duration, treatments, presence of anti-phospholipid antibodies and defining with carotid plaque yielded similar risk estimates.

Conclusion: In this analysis we confirm an elevated long-term risk of important adverse clinical events in patients with SLE compared with controls. A measure of cIMT is associated with incident CV event and mortality. This suggests that assessment with carotid ultrasound may have a value for CV risk stratification and would encourage validation in large-cohort prospective populations.

Disclosure of Inter: Sofia Ajejanova: None declared, Ingiläid Hafström: None declared, Johan Frostegård Shareholder of: Minor shareholder and inventor in startup-company Athera Biotechnologies, but they do not produce drugs yet and rheumatology is not in their focus.

DOI: 10.1136/annrheumdis-2019-eular.5763

THU0257

DIAGNOSTIC PERFORMANCE OF 2002 AECG, 2012 ACR AND 2016ACR/EULAR CLASSIFICATION CRITERIA FOR SJÖGREN'S SYNDROME IN A HISPANIC POPULATION

Nicolás Alfaro¹, Janett Carmen Riegatorres¹, Cesar Vidal Solis¹, David Vega Morales¹, Brenda Roxana Vázquez Fuentes¹, Mario Alberto Garza Elizondo¹, Cassandra Michele Skinner Taylor¹, Dionicio Ángel Galarza-Delgado¹, Jesús Mohamed Noriega², Karim Mohamed Noriega². ¹Hospital Universitario Dr. José Eleuterio González, Department of Rheumatology and Clinical Immunology, Monterrey, Nuevo León, Mexico; ²Hospital Universitario Dr. José Eleuterio González, Department of Ophthalmology, Monterrey, Nuevo León, Mexico

Background: Primary Sjögren's syndrome (pSS) has several classification criteria, whose diagnostic performances vary depending on the studied population¹. Concordance and differences among these criterias should be evaluated for independent populations to determine the diagnostic performance.

Objectives: To compare the performance among 3 classification criteria for pSS and determine the level of concordance among them.

Methods: Descriptive, retrospective, and cross-sectional study including 172 patients from the Rheumatology Service of the Hospital Universitario "Dr. José Eleuterio González", who were studied for dry syndrome. The clinical criterion of the attending physician was considered as the gold standard for diagnosis. Different parameters were collected: presence of xerostomia, xerophthalmia, Schirmer's test, sialometry, ocular staining, ANA, anti-Ro/SSA and anti-La/SSB antibodies, RF isotypes (IgA, IgM, IgG), and focal lymphocytic infiltrate in minor salivary gland biopsy. The criteria proposed by the American European Consensus Group (AECG), ACR and, ACR/EULAR were used to evaluate the classification. Compliance was determined for each set of criteria.

Results: Sociodemographic characteristics and clinical manifestations are shown in Table 1. For the AECG, ACR, and ACR/EULAR criteria, the sensitivity was 89.1%, 98.9% and 88% and the specificity was 93.8%, 71.3%, and 96.3%, respectively (Table 2). The ACR/EULAR criteria have an adequate level of agreement (k=0.663, P<0.001) with those of the AECG and with respect to the ACR criteria a moderate level of agreement (k=0.561, P<0.001).

Abstract THU0257 – Table 1. Clinical characteristics.

	pSS* n=92	Dry Syndrome n=80	P
Age, Median (IQR)	53[47-64]	51[43-59]	0.214
Female, n (%)	89(97%)	74(93%)	0.213
Xerostomia, n (%)	77/90 (86%)	52/71(73.2%)	0.052
xerophthalmia, n (%)	79/89 (89%)	58/69 (84%)	0.307
Schirmer test, n (%)	63 (68%)	36 (45%)	0.002
OSS $\geq$ 3, n (%)	60 (65%)	18 (22%)	<0.001
OSS $\geq$ 5, n (%)	59/91 (64%)	11/56 (19%)	<0.001
USF <1.5 ml/15 min, n (%)	74 (80%)	35 (43.8%)	<0.001
USF $\leq$ 0.1 ml/min, n (%)	76 (83%)	35 (43.8%)	<0.001
Minor Salivary Gland, n (%)	73/85 (86%)	23/67(34.5%)	<0.001
Anti-Ro/SSA, n (%)	70/90(78%)	5/69(7%)	<0.001
Anti-La/SSB, n (%)	27/86(31%)	1/65(2%)	<0.001
ANA, n (%)	62/88 (65%)	23/66 (35%)	<0.001
Rheumatoid Factor, n (%)	51/88 (58%)	24/66 (36%)	0.008
IgG, n (%)	17/86 (20%)	7/67 (10%)	0.116
IgM, n (%)	50/85 (59%)	23/63 (36%)	0.017
IgA, n (%)	34/83 (41%)	8/63 (13%)	0.001

OSS: Ocular Staining Score; USF: unstimulated salivary flow.

* The diagnosis of primary Sjögren's Syndrome was made based on clinical criteria *P< 0.001

Abstract THU0257 – Table 2. Diagnostic criteria performance.

		Kappa Cohen	
Sensitivity		2012	2016
2002 AECG	89.10%	0.545*	0.663*